Brief reportAbsence of Histologic Retinal Toxicity of Intravitreal Bevacizumab in a Rabbit Model
References (8)
- et al.
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration
Ophthalmic Surg Lasers Imaging
(2005) - et al.
Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration
Ophthalmology
(2006) - et al.
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion
Ophthalmic Surg Lasers Imaging
(2005) - et al.
Intravitreal bevacizumab (avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage
Retina
(2006)
Cited by (102)
Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study
2020, OphthalmologyCitation Excerpt :Although the CATT trial demonstrated that eyes receiving monthly treatment showed a higher incidence of atrophy compared with those being treated with PRN,16 the Alternative Treatments to Inhibit Vascular Endothelial Growth Factor in Patients with Age-Related Choroidal Neovascularization (IVAN) and RIVAL studies found no statistical difference in incidence of atrophy among differing anti-VEGF therapies.34,43 Injections of intravitreal anti-VEGF have been shown to have no association with RPE damage in animal models.44–46 A possible explanation for the inconsistent results reported in the literature is that MA could depend more on specific features of the single neovascular lesions included in the studies or the underlying MA phenotype, rather than on the treatment itself.
Chitosan grafted-poly(ethylene glycol) methacrylate nanoparticles as carrier for controlled release of bevacizumab
2019, Materials Science and Engineering CCitation Excerpt :Studies in vivo revealed the absence of ocular toxicity for BEV administrated by intravenous injection. Due to its short half-life and the necessity of frequent intravitreal injection, a method for sustained delivery is required [9–12]. Studies concerning BEV usefulness in the field of ophthalmology as an off-label drug for the treatment of wet AMD have been reported.
Cellular stress response in human Müller cells (MIO-M1) after bevacizumab treatment
2017, Experimental Eye ResearchCitation Excerpt :The concern that bevacizumab might be harmful to the retina has led researchers to evaluate its possible side effects through cell viability assays and the identification of molecules involved in cell death, proliferation and cell reactivity. While several experimental studies have failed to demonstrate any retinal toxicity from intravitreal injections of bevacizumab (Bakri et al., 2006; Feiner et al., 2006; Manzano et al., 2006; Zayit-Soudry et al., 2011), others have described ultrastructural abnormalities, including increased apoptotic activity (Saint-Geniez et al., 2008), increased glial cell reactivity (Fusco et al., 2012), and changes in retinal function (Myers et al.). In addition, newborn rat retinal explants exposed to bevacizumab have been shown to undergo molecular changes such as increased vimentin content, decreased GFAP (Miguel et al., 2012), and decreased neurocan mRNA levels (Krempel et al., 2014), potentially interfering with neuron and glial cell maturation early in the retinal development.
Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration
2013, OphthalmologyCitation Excerpt :Because VEGF antagonists are the best form of available treatment and consequently all treatable patients are treated with anti-VEGF drugs, the potential that these agents contribute to the development of RPE loss could not be evaluated. In rabbit eyes, intravitreal bevacizumab did not cause any observable damage.36,37 In cell culture, RPE cells exposed to hydrogen peroxide were more likely to die if either VEGF or the VEGF receptor was blocked by antibodies.38
Sustaining intravitreal residence with L-arginine peptide-conjugated nanocarriers
2017, Investigative Ophthalmology and Visual ScienceSafety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits
2020, International Journal of Retina and Vitreous
This study was funded by the Research to Prevent Blindness, New York, New York.